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One of the largest and most recent of these
studies reports adjusted odds for development of
coronary artery disease of 1.45 (95% confidence
interval [CI], 1.25–1.68) for subjects in the top
third of hs-CRP levels compared with those in the
bottom third.9 Odds ratios (OR) for other predic-
tors of coronary artery disease are higher 
than this, in particular total cholesterol
(OR=2.35; 95% CI, 2.03–2.74), cigarette smok-
ing (OR=1.87; 95% CI, 1.62–2.22), and elevated
systolic blood pressure (OR=1.50; 95% CI,
1.30–1.73). This shows that hs-CRP does not
contribute as much as these factors to the estab-
lished risk profile for coronary heart disease.
These same authors go on to provide a 
systematic review of 22 prospective studies of 
hs-CRP involving 7068 patients, which showed
that an elevated hs-CRP was associated with
higher odds of developing coronary artery disease
(OR=1.58; 95% CI, 1.48–1.68). They also exam-
ined the largest 4 studies in their review (which
included 4107 cases) and found a slightly lower
OR of 1.49 (95% CI, 1.37–1.62). This meta-analy-
sis included only studies published since 2000
because earlier studies, which had yielded higher
odds for hs-CRP, suggested a pattern consistent
with publication bias. 
Two very recent studies evaluating statin ther-
apy for CVD suggest that CRP may be monitored
as an independent factor for predicting CVD out-
comes for patients undergoing aggressive lipid
therapy.10,11 These randomized, masked trials sug-
gest that CRP is directly predictive of recurrent
events among patients with known CVD. Its use-
fulness may be greatest when trying to decide
whether to pursue aggressive (high-dose) statin
therapy for these patients.
It is not clear whether hs-CRP is a direct,
causative marker for atherosclerosis or whether
it is simply a proxy marker elevated in conjunc-
tion with other known risk factors. This issue,
combined with the fact that its elevation does not 
contribute as significantly as other risk factors,
makes hs-CRP an inappropriate screening test
for cardiovascular disease in the healthy adult 
10. Zhao XQ, Morse JS, Dowdy AA, et al. Safety and tolera-
bility of simvastatin plus niacin in patients with coronary
artery disease and low high-density lipoprotein choles-
terol (The HDL Atherosclerosis Treatment Study). 
Am J Cardiol 2004; 93:307–312.
11. Davignon J, Roederer G, Montigny M, et al. Comparative
efficacy and safety of pravastatin, nicotinic acid and the
two combined in patients with hypercholesterolemia. 
Am J Cardiol 1994; 73:339–345.
How useful is high-sensitivity
CRP as a risk factor 
for coronary artery disease?
■ EVIDENCE-BASED ANSWER
Little evidence supports the use of the high-sen-
sitivity C-reactive protein assay (hs-CRP) as a
screening test for cardiovascular disease (CVD)
in the healthy adult population. There is signifi-
cant debate about its use in populations at mod-
erate risk for cardiovascular disease, with some
evidence suggesting its use if the results of the
test will alter treatment recommendations1
(strength of recommendation [SOR]: C, based on
extrapolation of consistent level 2 studies).
Research to date is inadequate to determine the
role of hs-CRP in risk-stratification of patients
when considered in light of other standard risk
factors (Table).
■ EVIDENCE SUMMARY
C-reactive protein is a nonspecific serum marker
of inflammatory response. While it is elevated in
a variety of conditions, a link has been suggested
between CRP and pathogenesis of clinical cardio-
vascular disease.1
Several retrospective studies have reported
risk ratios for developing cardiovascular disease,
ranging from 2.3 to 4.4 when comparing subjects
with the highest levels of hs-CRP with those who
have the lowest levels.2–9 Though systematic bias
in retrospective study design limits the interpreta-
tion of these findings, the findings are of some
benefit to answering this question when large,
prospective, randomized studies are not available. 
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population. If results continue to accrue sup-
porting the relationship between statin therapy
and reduction of CVD outcomes attributable to
CRP, we may find that monitoring CRP levels
becomes appropriate in the management of
patients with known moderate or severe risk or
known disease.
■ RECOMMENDATIONS FROM OTHERS
A consensus statement from the American Heart
Association and the Centers for Disease Control
and Prevention discourages use of hs-CRP for
screening in the healthy adult population. It
offers support for using hs-CRP for assessment of
patients at medium risk levels for whom the test
will alter treatment decisions.1 Guidelines from
the Institute for Clinical Systems Improvement
for lipid management in adults state that, “non-
traditional risk factors (C-reactive protein [CRP]
and total homocysteine) have been shown to have
some predictive values in screening vascular dis-
ease. The value of screening for these risk factors
is not yet known.”12
Sharon K. Hull, MD, Department of Family Medicine,
Cecil G. Sheps Center for Health Services Research, University
of North Carolina at Chapel Hill, 
Linda J. Collins, MSLS, Health Sciences Library,
University of North Carolina at Chapel Hill
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Evidence-based use of C-reactive protein 
in cardiovascular disease
Known CV Framingham Screen with CRP Follow CRP along with 
disease risk score for risk assessment? lipids if treated with statins?
No Low risk (1%–5%) No No
No Moderate or high risk Little evidence to Only if trying to decide whether to 
(6% or higher) support screening use aggressive (high-dose) statin
therapy. In this situation, if moderate-
dose therapy does not lower CRP, 
consider this as a possible reason to 
Yes Any score No—disease is
move to higher doses.10,11 (strength
established, screening
of recommendation: B, based on 
is not appropriate
2 very recent level 2 studies)
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■ CLINICAL COMMENTARY
hs-CRP may be useful as a risk marker 
in some moderately high-risk patients
Elevated hs-CRP is not a standard cardiovascu-
lar risk factor, but may be useful for patients
with Framingham Risk scores of 10% to 20%.
The updated National Cholesterol Education
Panel Adult Treatment Panel III guidelines list
elevated hs-CRP (>3 mg/L) as an influencing
factor in deciding whether to use an LDL-lower-
ing drug for moderately high-risk patients with
LDL-cholesterol values <130 mg/dL.13 However,
no prospective studies prove that elevated hs-
CRP should guide therapy. The JUPITER trial is
a prospective, placebo-controlled trial evaluat-
ing cardiovascular events with statin therapy in
primary prevention patients with LDL values
<130 mg/dL and hs-CRP values >2 mg/L.14
When this study is completed, the definitive
clinical utility of hs-CRP will be known. Until
then, hs-CRP is a risk marker that may be use-
ful for some moderately high-risk patients.
Joseph Saseen, PharmD, FCCP, BCPS, University
of Colorado Health Sciences Center, Denver
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How should we follow up 
a positive screen for anemia 
in a 1-year old?
■ EVIDENCE-BASED ANSWER
Healthy infants who test positive for anemia on
routine screening at 1 year of age are most likely
iron-deficient and may be treated empirically with
a trial of iron therapy (3–6 mg of elemental
iron/kg/d). Documentation of response to iron
confirms the diagnosis of iron-deficiency (strength
of recommendation [SOR]: B; evidence from ran-
domized controlled trials with some conflicting
results; lack of evidence for long-term benefits/
harms of screening strategies). 
In these cases, further testing with a complete
blood count, mean corpuscular volume, red cell
distribution width (RDW), serum ferritin concen-
tration, as well as hemoglobinopathy screening
when appropriate,  may be effective in determin-
ing the cause of anemia (SOR: C, expert opinion).  
■ EVIDENCE SUMMARY
A prospective study of 1128 children identified as
anemic with a screening hemoglobin level showed
that subsequent testing—which included mean cor-
puscular volume, protoporphyrin, transferrin, and
ferritin measurements—did not reliably distinguish
potential responders from nonresponders to a 3-
month trial of empiric iron therapy.1 In fact, more
than half of the responders would have been missed
if treatment had been restricted to infants with
abnormal mean corpuscular volume or iron studies. 
Because of the simplicity, low cost, and relative
safety of iron therapy for infants, this trial sug-
gests that a therapeutic trial of iron be given first,
reserving further work-up for the small number of
infants that still have unexplained hemoglobin
concentrations of <11.0 g/dL after a therapeutic
trial. Similar results were found in a prospective
controlled treatment trial among Alaskan Native
children2 as well as a trial of empiric iron therapy
among infants with anemia.3
It is not clear whether hs-CRP is a
causative marker for atherosclerosis
or simply a proxy marker
